EyeCon 2026 Banner
|Articles|July 7, 2006

ISTA gains licenses to two investigational treatments for glaucoma

ISTA Pharmaceuticals gained exclusive North American rights to Senju Pharmaceuticals' iganidipine, a calcium-channel blocker, and a new formulation of latanoprost, a prostaglandin analogue.


Latest CME